Retatrutide Trends That Will Define Canadian Research in 2026
Understanding Retatrutide: The Triple-Agonist Paradigm Retatrutide, a synthetic lipopeptide developed by Eli Lilly, represents a significant advancement in metabolic therapy by simultaneously activating three key receptors involved in glucose metabolism and energy regulation: GIP, GLP-1, and glucagon. As the first single-molecule triple agonist, its potential to influence body weight and metabolic health has garnered considerable…